Study published in Cells. on the effects of ameliorating epigenetic modifications by ATP1A1 signalosome inhibition in the liver cancer of STAM™ mice

SMC is proud to announce that Marshall University (WV) has published the results of their study using our pre-clinical services with the STAM™ mice in Cells.


Title: Normalization of the ATP1A1 Signalosome Rescinds Epigenetic Modifications and Induces Cell Autophagy in Hepatocellular Carcinoma

(Rajan PK et al., Cells. 2023)   Article Link ► [DOI: 10.3390/cells12192367]


In this study, STAM™ mice were used as a pathological model for the development of liver cancer from metabolic dysfunction associated steatohepatitis, MASH (f.k.a. NASH).

We administered i.p. pNaKtide, an inhibitor of the ATP1A1/Src signalosome, to STAM™ mice in liver cancer phase and collected liver samples.

The authors used liver samples from these STAM™ mice to analyse epigenetic modifications such as histone acetylation and methylation in the liver. The frequency of H3K9ac and H3K9me3 was increased in the liver of STAM™ mice compared to normal mice, but decreased with pNaKtide treatment (Fig. 4 in this publication).

Previous study that have conducted similar experiment have also shown anti-cancer activity of pNaKtide against liver cancer in STAM™ mice (Udoh US et al., Int J Mol Sci. 2022 | DOI: 10.3390/ijms23137359).


As shown in this study, epigenetic modifications occur in the liver of STAM™ mice in the liver cancer phase.

STAM™ mice are useful for drug discovery and basic research, including the development of anti-cancer drugs focusing on epigenetic modifications.


If you are interested in STAM™ mice or have any questions, please feel free to contact us.